Research paper

EF-Tu from the enacyloxin producing *Frateuria* W-315 strain: Structure/activity relationship and antibiotic resistance

Jean-Bernard Créchet ^{a,*}, Christian Malosse ^b, Codjo Hountondji ^c

^a Ecole Polytechnique, Route de Saclay, F-91120 Palaiseau, France

^b Institut Pasteur, Département de Biologie Structurale et Chimie, Unité Spectrométrie de Masse Structurale et Protéomique, CNRS UMR 3528, 28 rue du Dr Roux, 75724 PARIS Cedex 15 France

^c Sorbonne Universités UPMC Univ Paris 06, Unité de Recherche UPMC UR6 "Enzymologie de l'ARN", 4, Place Jussieu, F-75252 Paris Cedex 05, France

A B S T R A C T

In this report, we have demonstrated that the poly(U)-dependent poly(Phe) synthesis activity of elongator factor Tu (EF-Tu) from the enacyloxin producing strain *Frateuria* sp. W-315 is inhibited by the antibiotic similarly to that of *Escherichia coli* EF-Tu. The inhibitory effect of enacyloxin observed in a purified system was the same as that obtained with an S30 extract from *E. coli* or *Frateuria* sp. W-315, respectively, suggesting that antibiotic resistance of enacyloxin producing *Frateuria* sp. W-315 is not due neither to EF-Tu nor to other components of the translation machinery but to a still unknown mechanism. The EF-Tu gene, as PCR amplified from *Frateuria* W-315 genomic DNA and sequenced represented an ORF of 1191 nucleotides corresponding to 396 amino acids. This protein is larger than the product of *tufA* from *E. coli* by only two amino acid residues. Alignment of the amino acid sequence of EF-Tu from *E. coli* with those of *Frateuria* and *Ralstonia solanacearum* indicates on average 80% identical amino acid residues and 9.7% conservative replacements between EF-Tu *Frateuria* and EF-Tu *E. coli*, on one hand, and 97% identity and 1.7% conservative replacement between EF-Tu *Frateuria* and EF-Tu *Ralstonia solanacearum*, on the other hand. These strong primary structure similarities between EF-Tu from different origins are consistent with the fact that this factor is essential for the translation process in all kingdoms of life. Comparison of the effects of antibiotics on EF-Tu *Frateuria* and EF-Tu *E. coli* revealed that enacyloxin, kirromycin and pulvomycin exert a stronger stimulation of the GDP dissociation rate on EF-Tu *Frateuria*, while the effects of the antibiotics on the GDP association rate were comparable for the two EF-Tu species. Different mutants of EF-Tu *E. coli* were constructed with the help of site directed mutagenesis by changing one or several residues of EF-Tu *E. coli* by the corresponding residues of EF-Tu *Frateuria*. The single A45K substitution did not modify the intrinsic GTPase activity of EF-Tu *E. coli*. In contrast, a 2–3 fold stimulation of the intrinsic GTPase activity was observed with the single A42E, F46Y, Q48E and the double F46Y/Q48E substitution. Finally, up to a 7 fold stimulation was observed with the quadruple substitution (mutant A42E/A45K/F46Y/Q48E).

Keywords:

Frateuria
Elongation factor Tu
Antibiotics resistance

1. Introduction

In all kingdoms of life, protein biosynthesis is promoted by two ribosomal subunits of unequal size (the small size subunit is 30S and 40S, and the large size subunit is 50S and 60S, in bacteria and in eukaryotes, respectively) with the help of a number of translation factors (reviewed in Ref. [1]). Among these factors, several such as

initiation factor 2 (IF2), elongation factors Tu (EF-Tu) and G (EF-G) and release factors 3 (RF3 and eRF3) are GTPases. EF-Tu forms a stable ternary complex with aminoacyl-tRNA (aa-tRNA) and GTP and this complex interacts with the ribosome and delivers aa-tRNA to the A-site [2]. Aa-tRNA delivery to the ribosomal A-site comprises several steps: (i) initial binding of the ternary complex to the ribosome is codon-independent; (ii) interaction between the anticodon of aa-tRNA and the A-site mRNA codon insures the correct positioning of the aa-tRNA prior to peptide bond formation at the ribosomal peptidyl transferase center (PTC). In fact, formation of a correct codon-anticodon duplex induces a dramatic

* Corresponding author.

E-mail address: jean-bernard.crechet@polytechnique.edu (J.-B. Créchet).

conformational change in the decoding site resulting in stabilization of the ternary complex on the ribosome. Furthermore, cognate codon recognition provides an activation signal that reaches the GTP-binding domain of EF-Tu and facilitates the formation of the activated GTPase state of the factor and the subsequent hydrolysis of the γ -phosphate of GTP; (iii) following the release of inorganic phosphate, the conformation of EF-Tu switches from the GTP to the GDP form which exhibits a low affinity for aa-tRNA. As a consequence, aa-tRNA is released from EF-Tu-GDP and is accommodated in the ribosomal 50S A-site in order to take part in peptide bond formation, while EF-Tu-GDP leaves the ribosome [3].

Owing to the essential role of translation in the rapid growth of pathogens sustaining bacterial infection, both 30S and 50S bacterial ribosomal subunits, as well as the translation factors are considered as valuable targets exhibiting several binding pockets for antibiotics, as deduced from the high-resolution structures of bacterial ribosomal subunits and those of their complexes with antibiotics [4,5]. Therefore, the discovery and development of new antibacterial agents has become a major topic in the post-crystal-structure era of the ribosome. In this context, an antibiotic consisting of a mixture of chemically related compounds was found to be produced by a bacterial *Frateruia* sp. W-315 strain. *Frateruia* W-315 strain has characteristics similar to those of *Gluconobacter* and produces a family of new polyenic antibiotics named enacyloxins which are active against Gram-negative and Gram-positive bacteria, only slightly active against fungi and not at all against yeast [6–8]. One of these compounds is enacyloxin IIa which was shown to inhibit bacterial protein biosynthesis *in vitro* [7]. EF-Tu was shown to be the specific target of enacyloxin [9]. EF-Tu is the target of three other families of antibiotics of unrelated structures [10,11], the prototypes of which are kirromycin, pulvomycin, and GE2270A. Enacyloxin IIa as kirromycin hinders the release of EF-Tu •GDP from the ribosome after GTP hydrolysis, thus inhibiting its recycling and peptide bond formation [9] while pulvomycin and GE2270A hinder the formation of the ternary complex between EF-Tu•GTP and aa-tRNA [12–14]. EF-Tu folds into three distinct domains, domain 1 being the nucleotide binding domain. Recent X-ray studies have revealed the tridimensional structures of EF-Tu-antibiotics complexes. In one of these studies, kirromycin and enacyloxin were shown to share the same binding site located at the interface between domains 1 and 3 [15,16]. Pulvomycin was shown to contact all three domains, while GE2270 was bound to domains 1 and 2 [15].

In the present report, we analyze the primary structure differences between EF-Tu from *E. coli* and EF-Tu from *Frateruia* sp. W 315, after having cloned and sequenced the gene coding for this factor. The biochemical characterization of EF-Tu *Frateruia*, followed by comparison with EF-Tu *Escherichia coli* in regard to the interaction with guanine nucleotides, the GTPase activity, the effects of antibiotics (specially enacyloxin) and the mutations in the effector region provide key insights into the structure/activity relationship of EF-Tu.

Another question that we have addressed in the present report is the search for key resistance mutations in the amino acid sequence of EF-Tu from *Frateruia* sp-315 (as compared with the one of *E. coli* EF-Tu) that might be responsible for the resistance to the antibiotic of this enacyloxin producing *Frateruia* strain.

2. Materials and methods

2.1. Purification of EF-Tu from *Frateruia* W-315

25 g of *Frateruia* W-315 cells obtained after 24 h at 25 °C from 2 L culture in LB medium were sonicated 12 times for 10 s at 4 °C in lysis buffer containing 50 mM Tris-HCl pH 7.5, 0.2 M NaCl, 5 mM

MgCl₂, 5 mM β -ME, 20 μ M GDP, 0.2 mg ml⁻¹ lysosyme, 20 μ g ml⁻¹ DNase, one tablet of complete mini EDTA free protease inhibitor cocktail (Roche Diagnostics), and centrifuged (30 000 g for 30 min). The obtained supernatant which constituted S30 extract was centrifuged again at 100.000 g for 1 h. Supernatant was dialysed against buffer A (25 mM Tris-HCl pH 7.5, 5 mM MgCl₂, 30 mM KCl, 7 mM β -ME, 20 μ M GDP), then loaded on Hi-Prep Source 30Q 16 $\times$ 10 (Äkta purifier system, GE Healthcare) using a linear 50–500 mM KCl gradient (700 ml) in the same buffer. The active EF-Tu containing fractions (determined as [³H]GDP binding on nitrocellulose filters) eluted between 150 and 200 mM KCl were concentrated by ultrafiltration, dialysed against buffer A and applied on Mono-Q HR5/5 (Äkta purifier system, GE Healthcare) with a 40 column volumes 50–300 mM KCl linear gradient in buffer A. The pooled and concentrated EF-Tu containing fractions (13 mg) were loaded on superdex 75 (16 $\times$ 60) GE Healthcare equilibrated in buffer A containing 0.2 M KCl. The most pure fractions (5 mg) as revealed on PAGE-SDS were collected, concentrated, dialysed against buffer A containing 50% glycerol and stored at –25 °C.

2.2. Determination of the amino acid sequence of tryptic peptides from purified *Frateruia* W-315 EF-Tu by mass spectrometry

2.2.1. Trypsin digestion

Sample in H₂O was reduced by one fifth volume of 10 mM dithiothreitol (Sigma Aldrich) in 0.1 M NH₄HCO₃ for 30 min at 56 °C under agitation and alkylated by 55 mM iodoacetamide in 0.1 M NH₄HCO₃. The carbamidomethylated protein was digested with trypsin (Roche) in a 1:35 protein:trypsin ratio overnight at 37 °C under agitation. Sample was taken directly from the digest and desalted by C18 ZipTip® (Millipore) before MS analysis in 75:25:0.1 acetonitrile/water/HCOOH (v/v/v). Protein solution was desalted by C4 ZipTip® (Millipore) and eluted in 10 μ l 75:25:3 MeOH/water/HCOOH (v/v/v) before mass spectrometry experiments.

2.2.2. Mass spectrometric analyses

MS and MS/MS experiments on tryptic peptides were performed on a quadrupole, orthogonal acceleration time-of-flight tandem mass spectrometer Q-TOF-Premier™ (Waters Corp., Milford, MA, USA). The proteins were ionized using nanoelectrospray ionization source heated at 80 °C, in positive mode (ZSpray™). Samples were introduced in the mass spectrometer via nanoelectrospray glass capillaries (ProXeon) filled with 2–5 μ L of the protein or peptides solution and subsequently opened by breaking the tapered end of the tip under a microscope. The tension on the capillary was tuned manually between 2.1 and 2.6 kV depending of the sample, and cone voltage set to 40 V. MS experiments were performed in wide pass quadrupole mode, with the TOF data being collected between 200 and 2000 Th with a low collision energy of 5 eV. Argon was used as the collision gas. Scans were collected for 1 s and accumulated to increase the signal/noise ratio. MS/MS experiments were performed using a variable collision energy (20–32 eV), which was optimised for each precursor ion. Mass Lynx 4.1 was used both for acquisition and data processing. Deconvolution of multiply charged ions into neutral species was realized using MaxEnt1 in the mass range [40–50 kDa] with a resolution of 1.0 or 0.1 Da/channel for proteins and MaxEnt3 with an appropriate mass range for peptides. External calibration was performed in MS with clusters of phosphoric acid (0.01 M in 50:50 acetonitrile:water) immediately before each experimental set.

2.3. Cloning and sequencing of EF-Tu *Frateruia* W-315

On the basis of amino acid sequence identities between EF-Tu from *Frateruia*, from *E. coli* and from *Ralstonia solanacearum*, as

determined by mass spectrometric analyses, an EF-Tu gene fragment of 445 bp was amplified using Pwo polymerase high fidelity PCR system (Roche Diagnostics) from *Frateuria* W-315 genomic DNA isolated following the instructions of E.Z.N.A bacterial DNA kit from OMEGA-Bio-tek and the 5' primer GGTACGTTACACCGG and the 3' primer CGTCGCCCGGAAGTC.

This DNA fragment was sequenced by GenoScreen. The 5' coding region of EF-Tu *Frateuria* was PCR amplified from *Frateuria* W-315 genomic DNA using a 5' primer sequence CCGCTGTCTGAAATGTTCCGATAC of *fusA1* gene, the upstream locus of *tuf* gene in genome sequence of *Ralstonia solanacearum* [17] and a 3' primer GATACCACGTGCTTTTCTCCGG corresponding to a 5' region of the identified sequence of the PCR 445 bp fragment of *Frateuria* EF-Tu. The 3' coding region of EF-Tu *frateuria* was PCR amplified from *Frateuria* W-315 genomic DNA using a 5' primer sequence GTGGACGACGCTGAAGTCTG corresponding to a 3' region of the identified sequence of the PCR 445 bp fragment of *Frateuria*. EF-Tu and a 3' primer GCCTTCAGGCGGATACGGAT corresponding to a sequence belonging to *rpsJ* gene downstream of the *tuf* gene in *Ralstonia solanacearum* genome sequence. The amplified fragments were purified and sequenced. The overlapped sequences allowed the determination of the complete ORF of the gene encoding EF-Tu from *Frateuria* W-315.

The coding sequence was amplified from *Frateuria* W-315 genomic DNA using the 5' primer CGTGGATCCGCAAAAGA-GAAGTTCGAACGGACCAAG and the 3' primer GATGAATCTTAGTC-GAGGATCTGGCGACGACGCC respectively containing the *Bam*H1 and *Eco*R1 sites (underlined) and cloned after digestion and purification into the *Bam*H1-*Eco*R1 sites of the vector pGEX-2T. Accuracy of the amplification was controlled by sequencing of the cloned gene.

2.4. Purification of recombinant *Frateuria* W-315 EF-Tu and *E. coli* EF-Tu mutants

The different species of EF-Tu were overproduced in *E. coli* strain DH5 α as fusion with glutathione S-transferase [18]. The transformed *E. coli* strains were grown at 37 °C in 2 L of LB rich medium containing 50 μ g ml⁻¹ ampicillin to 0.5 A₆₀₀, after which induction with 0.1 mM isopropyl- β -D-thiogalacto-pyranoside took place at 23 °C with incubation up to 17 h. Under these conditions, high level of soluble EF-Tu was obtained.

After harvest, the cells were washed in PBS, sonicated 15 times for 10 s at 4 °C in 40 ml buffer B (50 mM Tris-HCl pH 7.5, 0.15 M NaCl, 7 mM β -ME, 5 mM MgCl₂ containing 0.5 mg ml⁻¹ lysosyme, 100 μ g ml⁻¹ DNase, one tablet of complete mini EDTA free protease inhibitor cocktail (Roche Diagnostics), and centrifuged (100,000 g for 30 min). The extract supernatant was mixed for 30 min at 4 °C with 3 ml glutathione sepharose 4 fast flow (GE healthcare). The suspension was washed several times with buffer B, then with buffer C (25 mM Tris-HCl pH 8.0, 2.5 mM CaCl₂, 1 mM MgCl₂, 30 mM KCl, 10 μ M GDP) before incubation 3 times at 30 °C for 15 min with 25 U thrombin (Sigma) for removing N-terminal fused glutathione S-transferase, 1 mM Pefablock-SC (Roche Diagnostics) was then added. The last step of purification of the different EF-Tu species was a Mono Q-HR 5/5 chromatography (Äkta purifier system, GE Healthcare) with a linear gradient 50–300 mM KCl gradient (50 ml) in buffer D (25 mM Tris-HCl pH 7.5, 1 mM MgCl₂, 7 mM β -ME, 10 μ M GDP). After concentration by ultrafiltration, EF-Tu preparations were dialysed and stored at -25 °C in buffer D containing 50% glycerol.

2.5. Site-directed mutagenesis

Mutations were introduced with the QuickChange II XL Site-

Directed Mutagenesis Kit and by using the manufacturer (Stratagen) recommended protocol. As a substrate for the mutagenesis reactions we used pGtAM, a derivative of pGEX-2T $tufA$ [19] which codes for a thrombin-cleavable glutathione S-transferase-fused *E. coli* EF-Tu. The mutagenic oligonucleotides for the amino acid substitutions were 5'-CCTACGGCGGTGAAGCTCGTGCATTCCAGCAG-3' for A42E, 5'-GCCGTGCTGCTCGTAAGTTCGACCAGATCG-3' for A45K, 5'-GCTGCTCGTGCATACGACCAGATCGATAACG-3' for F47Y, 5'-CGTGCAATTCGACGAGATCGATAACGCGCCG-3' for Q48E, 5'-GCTAAAACCTACGGCGGTGAAGCTCGTAA GTACGACGAGATCGATAACG-3' for A42E/A45K/F46Y/Q48E (modified bases underlined) and their respective complementary mutagenic primers. Following transformation of competent XL10-Gold cells, minipreps on selected transformants were analyzed by sequencing to verify the presence of desired mutations and to check the absence of secondary mutations.

2.6. Biological materials

Poly(U) and tRNA^{Phe} from *E. coli* were from Sigma-Aldrich and L-[¹⁴C(U)]Phenylalanine (18 GBq.mmol⁻¹) from Perkin Elmer. Kirromycin was obtained from Gist-Brocades (Delft, The Netherlands), GE2270A from Drs E.Selva & M. Denaro, (Lepetit Research Centre), and Enacyloxin IIa and IVa from Dr T. Watanabe, while Pulvomycin was isolated according to Smith et al. [20], tRNA^{Phe} was aminoacylated using [¹⁴C(U)]Phenylalanine with an excess amount of partially purified phenylalanyl-tRNA synthetase from *E. coli* as in Ref. [21]. *E. coli* 70S Ribosomes were prepared as reported in Ref. [21]. EF-Ts was purified as recombinant protein [22].

Fus gene encoding EF-G was amplified from total cellular DNA from *E. coli* strain MRE600 using the 5' primer CACCATGGCTCG-TACAACACCCATC and the 3' primer TTTACCACGGGCTTCAAT-TACGGC. The amplified fragment was cloned into pET101/D-TOPO vector using Champion pET directional TOPO expression kit from invitrogen. 6His-tagged EF-G was expressed in BL21 Star (DE3) *E. coli* strain. The culture induced at a cell density of 0.5 A₆₀₀ with 0.2 mM isopropyl- β -D-thiogalacto-pyranoside was collected after 6 h of growth at 28 °C in LB medium containing ampicillin. After harvest, cells were sonicated 12 times for 10 s at 4 °C in buffer A (20 mM sodium phosphate pH 7.5, 0.5 M NaCl, 20 mM imidazole, 5 mM β -ME) containing 0.5 mg ml⁻¹ lysosyme, 100 μ g ml⁻¹ DNase, one tablet of complete mini EDTA free protease inhibitor cocktail (Roche Diagnostics), and centrifuged (100,000 g for 30 min). Supernatant was applied on 1 ml His GraviTrap affinity column (GE Healthcare) equilibrated with buffer A, the column was washed with the same buffer before elution of the protein in buffer A containing 0.5 M imidazole. The eluted fraction containing EF-G was dialysed against buffer B (25 mM Tris-HCl pH 7.5, 1 mM MgCl₂, 60 mM KCl, 7 mM β -ME) and loaded on MonoQ HR 5/5 column (Äkta purifier system, GE Healthcare) using a linear 60–500 mM KCl gradient (50 ml) in buffer B. After concentration by ultrafiltration, EF-G factor preparation was stored at -20 °C in buffer B containing 50% glycerol. Pulvomycin, Kirromycin and enacyloxin were used as stable 20 mg/ml stock solution dissolved in methanol and kept at -25 °C.

2.7. Enzymatic assays

Poly(Phe) synthesis was determined as incorporation of L-[¹⁴C(U)]Phenylalanine into hot trichloroacetic acid-insoluble material as described in Ref. [23]. The reaction mixture contained 40 mM Tris-HCl pH 7.5, 7 mM MgCl₂, 80 mM NH₄Cl, 1 mM dithiothreitol, 1 mM ATP, 1 mM phosphoenolpyruvate, 0.5 mM GTP,

50 $\mu\text{g ml}^{-1}$ pyruvate Kinase, 5 μM tRNA^{Phe} (first charged during a 30 min incubation at 30 °C with a 2 fold excess of L-[¹⁴C(U)] Phenylalanine (5 GBq.mmol⁻¹) and a saturating amount of partially purified phenylalanyl-tRNA synthetase), 3.5 μg poly(U) and antibiotic, 70S ribosomes, elongation factors or S30 extract as described in legends to figures. After incubation aliquots were withdrawn spotted on glass fiber filters and hot trichloroacetic acid insoluble radioactivity was determined in a Wallac 1410 (Perkin Elmer life sciences) scintillation spectrometer.

Association rates of EF-Tu proteins with GDP or GTP and dissociation rates of EF-Tu•GDP and EF-Tu•GTP complexes were determined at 0 °C in standard buffer 50 mM Tris HCl pH 7.5, 5 mM MgCl₂, 60 mM NH₄Cl, 0.05 mg.mL⁻¹BSA, 1 mM dithiothreitol in absence or presence of 50 μM antibiotic, using the nitrocellulose filtration procedure [24].

For the determination of association rates, nucleotide free EF-Tu proteins were prepared after incubation of pure EF-Tu•GDP proteins (100–150 pmol in 30 μl) for 20 min at 30 °C in 25 mM Tris-HCl, pH 7.5, 100 mM (NH₄)₂SO₄, 10 mM NaEDTA, 1 mM dithiothreitol. The solution was passed through a Sephadex G25 medium column (18 × 0.4 cm) at 4 °C equilibrated with in 25 mM Tris-HCl, pH 7.5, 500 mM (NH₄)₂SO₄, 0.5 mM NaEDTA, 7 mM β -mercaptoethanol. 0.25 mg mL⁻¹ BSA. A final concentration of 6 mM MgCl₂ was added to the GDP-free EF-Tu containing fraction.

Prior to each GTP-containing assay, 5 μM [³H]GTP (specific activity, 160 Bq pmol⁻¹, Perkin Elmer life sciences) was preincubated in standard buffer for 10 min at 30 °C with 10 μg pyruvate kinase and 0.4 mM phosphoenolpyruvate.

Association rates of EF-Tu with GTP or GDP were measured in standard buffer containing 2–30 nM nucleotide-free EF-Tu and 5–100 nM [³H]GTP or 4–10 nM [³H]GDP (specific activity, 200 Bq pmol⁻¹, Perkin Elmer life sciences). The reaction was started with labeled nucleotide. Aliquots of the reaction mixture were withdrawn every 10 s for 2-min period and filtered on nitrocellulose discs that were washed twice with 3 ml ice-cold 25 mM Tris-HCl pH 7.5, 10 mM MgCl₂, 60 mM NH₄Cl; 7 mM β -mercaptoethanol. The nitrocellulose membranes were then counted for radioactivity. The apparent second order rate constants for association of EF-Tu products and guanine nucleotides were calculated according to the equation $1/(b-a)\ln[a(b-x)/b(a-x)] = k'_{+1}t$ where a is the initial concentration of [³H]GTP or [³H]GDP, b is the initial concentration of nucleotide-free EF-Tu proteins and x is the concentration of EF-Tu•[³H]GTP or EF-Tu•[³H]GDP complexes formed at the different time, t . The initial concentration b was determined from the radioactivity bound to each GDP-free EF-Tu products in the presence of a saturating amount of [³H]GTP or [³H]GDP after 10 min incubation in standard buffer at 30 °C.

For determination of dissociation rate constants (k_{-1}), preformed labeled EF-Tu•[³H]GTP or EF-Tu•[³H]GDP complexes were prepared by incubating for 15 min at 30 °C 5 μM EF-Tu•GDP in 25 mM Tris-HCl pH 7.5, 5 mM EDTA, 1 mM dithiothreitol and 0.05 mg mL⁻¹ BSA with 10 μM [³H]GTP or 15 μM [³H]GDP (400 Bq pmol⁻¹), then stabilized by adding 10 mM MgCl₂ in standard buffer. The dissociation rates was started with 250 nM preformed EF-Tu•[³H]GTP or EF-Tu•[³H]GDP complex in 95 μl reaction mixture containing a 1000 fold excess of the corresponding nonlabeled nucleotide. At time intervals aliquots (10 μl) were filtered on nitrocellulose discs that were then washed and counted as described above.

For GTPase activity EF-Tu[γ -³²P]•GTP complexes were preformed by incubating around 2 μM EF-Tu•GDP at 30 °C for 10 min with 100 μM [γ -³²P]•GTP (20 Bq. pmol⁻¹) in 25 mM Tris-HCl pH 7.5, 5 mM EDTA, 1 mM dithiothreitol and 0.05 mg mL⁻¹ BSA and then stabilized by the addition of 10 mM MgCl₂.

GTPase activity was determined in 82 μl reaction mixture containing 40 mM Tris-HCl pH 7.5, 7 mM MgCl₂, 80 mM NH₄Cl, 1 mM

Fig. 1. Poly(U)-directed poly(phe) synthesis as function of increasing concentrations of enacyloxin determined (A) in the presence of enacyloxin IIa and purified components of the translational machinery including purified EF-Tu from *E. coli* (○) or purified EF-Tu from *Frateuria* W315 (□); (B) in the presence of enacyloxin IIa and S30 extracts from *E. coli* (○) or from *Frateuria* W315 (□), (C) in the presence of enacyloxin IVa and S30 extracts from *E. coli* (○) or from *Frateuria* W315 (□). The final reaction mixture (70 μl) described in the Methods contained the indicated concentrations of the two forms of Enacyloxin and in A: 100 nM EF-G, 220 nM 70S ribosomes, 250 nM EF-Tu from *E. coli* or from *Frateuria* W315, 250 nM EF-Ts. In B and C: 80 μg S30 extracts from *E. coli* MRE600 or from *Frateuria* W315. The reaction was started by the addition of [¹⁴C]Phe-tRNA^{Phe} and stopped after 6 min incubation at 30 °C under conditions of linear Phe incorporation. The results are expressed as a percentage of the activity obtained in the absence of the antibiotic and are the average of three independent experiments.

dithiothreitol, 200–300 nM preformed EF-Tu[γ -³²P]•GTP complex with or without 50 μM antibiotic. The hydrolysis of [γ -³²P]•GTP was measured at 30 °C by following the liberation of γ -³²Pi in time using the charcoal method: 10 μl aliquots were withdrawn and the reaction was stopped with 300 μl of a 4% suspension of activated charcoal in 20 mM H₃PO₄.

After centrifugation the radioactivity in 200 μl supernatant was

counted. The amount of GTP hydrolysis obtained in the absence of EF-Tu was subtracted.

3. Results

3.1. Effect of enacyloxin on protein biosynthesis in vitro sustained by EF-Tu from *Frateruia* W-315

Elongation factor Tu was previously shown to be the specific target of enacyloxin [9]. The antibiotic hinders the release of EF-Tu•GDP from the ribosome after GTP hydrolysis, thus inhibiting its recycling and peptide bound formation [9].

After having purified to homogeneity EF-Tu from *Frateruia* W-315 following the procedure described in Methods, we have determined the effect of enacyloxin by using an *in vitro* poly(Phe) synthesis assay catalysed by purified translational components from *E. coli*.

We expected that the EF-Tu-dependent poly(Phe) synthesis activity of *Frateruia* sp. W-315 would be insensitive to increasing concentrations of enacyloxin IIa, insofar as this antibiotic is produced by the strain itself. Unexpectedly, poly(U)-dependent poly(Phe) synthesis assay with EF-Tu from *Frateruia* sp. W-315 was inhibited by the antibiotic similarly to the one with *E. coli* EF-Tu at a concentration of about 0.2 μ M (IC_{50}) (Fig 1A).

The effect of enacyloxin IIa was then measured on poly(Phe) synthesis sustained by S30 extract from *E. coli* and *Frateruia* W-315, respectively. As shown in (Fig 1B), the inhibitory effect of enacyloxin IIa was almost the same as that obtained in the purified system.

In the early phase of production of enacyloxins by *Frateruia* W-315, enacyloxin IVa was first secreted, followed by its conversion to enacyloxin IIa [25] by an extracellular quinoprotein oxidase. The possibility that *Frateruia* EF-Tu would be more resistant to the intermediate Enacyloxin IVa than to the end product Enacyloxin IIa was checked by measuring the effect of Enacyloxin IVa on the

poly(U)-dependent poly(Phe) synthesis assay sustained by S30 extract from *Frateruia* sp. W-315. As shown in Fig. 1C, the sensitivity was the same that with the final product. These results strongly suggest that antibiotic resistance of enacyloxins producing *Frateruia* W-315 is not due neither to EF-Tu nor to other components from the translation apparatus like the ribosomes, but rather to other independent factors.

3.2. Sequencing, cloning and purification of cloned EF-Tu from *Frateruia* W-315

Purified EF-Tu from *Frateruia* W-315 was subjected to trypsin digestion and mass spectrometric analyses (Fig. 2).

First, primary structure similarities between EF-Tu *Frateruia* W-315 and EF-Tu *Ralstonia solanacearum*, an aerobic non sporing gram negative plant pathogenic bacterium [17] were identified with the FASTA program. Thereafter, EF-Tu gene was PCR amplified from *Frateruia* W-315 genomic DNA following the procedure described in Methods, and sequenced. The DNA sequence (Fig. 3) shows an ORF of 1191 nucleotides corresponding to 396 amino acids. This protein is larger than the product of *tufA* from *E. coli* by only two residues.

Alignment of the amino acid sequence of EF-Tu from *E. coli* with those of *Frateruia* and *Ralstonia solanacearum* indicates on average 80% identical amino acid residues and 9.7% conservative replacements between EF-Tu *Frateruia* and EF-Tu *E. coli*, on one hand, and 97% identity and 1.7% conservative replacement between EF-Tu *Frateruia* and EF-Tu *Ralstonia solanacearum*, on the other hand (Fig. 4). These strong primary structure similarities between EF-Tu from different origins are consistent with the fact that this factor is essential for the translation process in all kingdoms of life. The major difference in the primary structure between the three aligned factors resides in fragment 36–48 located in the so called “effector region”.

The coding sequence amplified from *Frateruia* genomic DNA was

fragment	Mr expt	Mr theor	delta	sequence
9-25	1794.9512	1794.9489	0.0023	R.TKPHVNVGTIGHVDHGK.T
26-39	1375.7758	1375.7922	-0.0164	K.TTLTAAIATVLSSK.F
46-57	1406.6519	1406.6565	-0.0046	K.KYDEIDAAPEEK.A
60-75	1801.8802	1801.8958	-0.0156	R.GITINTAHIEYETANR.H
76-90	1767.7575	1767.7787	-0.0212	R.HYAHVDCPGHADYVK.N Carbamidomethyl (C)
91-117	2775.2483	2775.2812	-0.0329	K.NMITGAAQMDGAILVCSAADGPMPTQR.E Carbamidomethyl (C)
118-124	850.4959	850.5025	-0.0065	R.EHILLAR.Q
138-155	2164.9444	2164.969	-0.0246	K.CDMVDDAELLELVEMEVR.E Carbamidomethyl (C)
161-172	1379.6541	1379.6609	-0.0068	K.YDFPGDDTPIIK.G
208-226	2038.9889	2039.0034	-0.0145	R.AVDGTFMLPVEDVFSISGR.G
241-251	1184.6574	1184.6652	-0.0078	K.VGEEIEIVGIK.A
256-265	1200.5214	1200.5267	-0.0053	K.TTCTGVEMFR.K Carbamidomethyl (C)
266-282	1809.0044	1809.0108	-0.0064	R.KLLDQGGAGDNVIGILLR.G
267-282	1680.8997	1680.9159	-0.0162	K.LLDQGGAGDNVIGILLR.G
322-336	2032.9453	2032.9697	-0.0243	R.HTPPFNRYRPFYFR.T
337-348	1259.6514	1259.6609	-0.0095	R.TTDVTGSIPLK.D
337-350	1502.7725	1502.7828	-0.0103	R.TTDVTGSIPLPKDK.E
349-364	1761.857	1761.8641	-0.0071	K.DKEMVMMPGDNVISITVK.L
349-364	1777.8168	1777.859	-0.0422	K.DKEMVMMPGDNVISITVK.L Oxidation (M)
351-364	1518.7401	1518.7422	-0.0021	K.EMVMMPGDNVISITVK.L
351-364	1550.7246	1550.732	-0.0074	K.EMVMMPGDNVISITVK.L 2 Oxidation (M)
365-376	1311.7102	1311.722	-0.0118	K.LIAPIMEEGLR.F
385-393	800.4761	800.4756	-0.0005	R.TVGAGVVAK.I

Fig. 2. Mass spectrometric analyses of tryptic peptides from EF-Tu *Frateruia* W 315.

```

1/1                               31/11                               61/21
|                               |                               |
ATG GCA AAA GAG AAG TTC GAA CGG ACC AAG CCG CAC CAC AAC GTC GGT ACG ATC GGT CAC GTT GAC CAC GGC AAG ACG ACG CTG ACG GCA
M  A  K  E  K  F  E  R  T  K  P  H  V  N  V  G  T  I  G  H  V  D  H  G  K  T  T  L  T  A

91/31                             121/41                             151/51
|                               |                               |
GCC ATC GCA ACG GTT CTG TCG TCG AAG TTC GGC GCG GAA GCG AAG AAG TAC GAC GAA ATC GAT GCG GCG CCG GAA GAA AAG GCA CGT GGT
A  I  A  T  V  L  S  S  K  F  G  G  E  A  K  K  Y  D  E  I  D  A  A  P  E  E  K  A  R  G

181/61                           211/71                           241/81
|                               |                               |
ATC ACG ATC AAC ACC GCG CAC ATC GAG TAC GAA ACG GCG AAC CCG CAC TAC GCA CAC GTC GAT tGC CCG GGC CAC GCC GAC TAC GTG AAG
I  T  I  N  T  A  H  I  E  Y  E  T  A  N  R  H  Y  A  H  V  D  C  P  G  H  A  D  Y  V  K

271/91                           301/101                          331/111
|                               |                               |
AAC ATG ATC ACG GGT GCC GCG CAG ATG GAC GGC GCG ATC CTG GTG TGC TCG GCC GCC GAC GGC CCG ATG CCG CAA ACG CGT GAG CAC ATC
N  M  I  T  G  A  A  Q  M  D  G  A  I  L  V  C  S  A  A  D  G  P  M  P  Q  T  R  E  H  I

361/121                          391/131                          421/141
|                               |                               |
CTG CTG GCG CGT CAG GTT GGC GTT CCG TAC ATC ATC GTG TTC CTG AAC AAG TGC GAC ATG GTG GAC GAC GCT GAA CTG CTC GAG CTG GTC
L  L  A  R  Q  V  G  V  P  Y  I  I  V  F  L  N  K  C  D  M  V  D  D  A  E  L  L  E  L  V

451/151                          481/161                          511/171
|                               |                               |
GAG ATG GAA GTT CCG GAA CTC CTG TCG AAG TAC GAC TAC CCG GGC GAC GAC ACG CCG ATC ATC AAG GGT TCG GCG AAG CTG GCG CTG GAA
E  M  E  V  R  E  L  L  S  K  Y  D  F  P  G  D  D  T  P  I  I  K  G  S  A  K  L  A  L  E

541/181                          571/191                          601/201
|                               |                               |
GGC GAC AAG GGC GAG CTG GGC GAG ACG GCG ATC ATG AGC CTG GCC GAC GCG CTG GAC ACG TAC ATC CCG ACG CCG GAG CGC GCG GTC GAC
G  D  K  G  E  L  G  E  T  A  I  M  S  L  A  D  A  L  D  T  Y  I  P  T  P  E  R  A  V  D

631/211                          661/221                          691/231
|                               |                               |
GGT ACG TTC CTG ATG CCG GTG GAA GAC GTG TTC TCG ATC TCG GGT CCG GGC ACG GTG GTG ACG GGT CGT GTC GAG CGT GGC ATC GTG AAG
G  T  F  L  M  P  V  E  D  V  F  S  I  S  G  R  G  T  V  V  T  G  R  V  E  R  G  I  V  K

721/241                          751/251                          781/261
|                               |                               |
GTC GGC GAG GAA ATC GAA ATC GTC GGC ATC AAG GAC ACG CAG AAG ACG ACC TGC ACG GGC GTG GAA ATG TTC CCG AAG CTG CTG GAC CAA
V  G  E  E  I  E  I  V  G  I  K  D  T  Q  K  T  T  C  T  G  V  E  M  F  R  K  L  L  D  Q

811/271                          841/281                          871/291
|                               |                               |
GGT CAG GCT GGC GAC AAC GTG GGT ATC CTG CTG CCG GGT ACG AAG CGT GAA GAC GTG GAG CGT GGC CAG GTT CTG GCC AAG CCG GGT TCG
G  Q  A  G  D  N  V  G  I  L  L  R  G  T  K  R  E  D  V  E  R  G  Q  V  L  A  K  P  G  S

901/301                          931/311                          961/321
|                               |                               |
ATC AAG CCG CAC ACG CAC TTC ACG GCT GAA GTG TAC GTG CTG AGC AAG GAC GAA GGC GGC CGC CAC ACG CCG TTC TTC AAC AAC TAC CGT
I  K  P  H  T  H  F  T  A  E  V  Y  V  L  S  K  D  E  G  G  R  H  T  P  F  F  N  N  Y  R

991/331                          1021/341                         1051/351
|                               |                               |
CCG CAG TTC TAC TTC CGT ACG ACG GAC GTG ACG GGC TCG ATC GAG CTG CCG AAG GAC AAG GAA ATG GTC ATG CCG GGC GAC AAC GTG TCG
P  Q  F  Y  F  R  T  T  D  V  T  G  S  I  E  L  P  K  D  K  E  M  V  M  P  G  D  N  V  S

1081/361                         1111/371                         1141/381
|                               |                               |
ATC ACG GTG AAG CTG ATC GCT CCG ATC GCG ATG GAA GAA GGT CTG CCG TTC GCG ATC CCG GAA GGC GGC CGT ACC GTC GGC GCC GGC GTC
I  T  V  K  L  I  A  P  I  A  M  E  E  G  L  R  F  A  I  R  E  G  G  R  T  V  G  A  G  V

1171/391
|
GTC GCC AAG ATC CTC GAC TAA
V  A  K  I  L  D  *

```

Fig. 3. Nucleotide sequence of the gene encoding EF-Tu from *Frateruia* W 315 and the amino acid sequence deduced.

cloned in pGEX-2T, overproduced as fusion with glutathione S-transferase in *E. coli* strain DH5 α and purified free of fused GST after thrombin treatment.

3.3. Comparison of the dynamics of interaction between GDP or GTP and EF-Tu *Frateruia* or EF-Tu *E.coli* and the effects of antibiotics

Table 1 shows the apparent association and dissociation rates constants and the derived dissociation constant ($K'_D = k'_{-1}/k'_{+1}$) of EF-Tu•GDP *Frateruia* and EF-Tu•GDP *E. coli* complexes and the respective effect of the antibiotics enacyloxin, kirromycin, pulvomycin and GE2270A. These antibiotics are well known to act specifically on EF-Tu [9,12,13,21,24,26]. Due to a decrease of the dissociation rate and a modest increase of the association rate, the affinity of EF-Tu *Frateruia* for GDP was found to be 3 times higher than that of EF-Tu *E. coli* (Table 1).

Comparison of the effects of antibiotics on EF-Tu *Frateruia* and

EF-Tu *E. coli* revealed that enacyloxin, kirromycin and pulvomycin exert a stronger stimulation of the GDP dissociation rate on EF-Tu *Frateruia*, while the effects of the antibiotics on the GDP association rate were comparable for the two EF-Tu species. No effect on the dissociation rate was observed with GE2270A while it inhibited almost 4 fold the association rate for EF-Tu *Frateruia*. As for the interaction with GTP (Table 2), due to an increase of the association rate, the affinity of EF-Tu *Frateruia* was found to be 2.5 times higher than that for EF-Tu *E. coli*. All the used antibiotics were shown to increase the affinity of the two EF-Tu species for GTP. While each antibiotic was shown to reduce the GTP dissociation rates to approximately the same extent for the two EF-Tu species, their effects on the stimulation of the GTP association rate were lower for EF-Tu *Frateruia* than for EF-Tu *E. coli*. In particular, enacyloxin was shown to exert a stimulation more than 8 times lower.

EF_Tu-Frat	MAKEKFERTKPHVNVGTIGHVDHGKTTLTAAIATVLSSKFGGEAKKYDEIDAAPEEKARG	60
EF_Tu-Rals.so	MAKEKFERTKPHVNVGTIGHVDHGKTTLTAAIATVLSSKFGGEAKKYDEIDAAPEEKARG	60
EF_Tu-EColi	-SKEKFERTKPHVNVGTIGHVDHGKTTLTAAITTVLAKTYGGAARAFDQIDNAPEEKARG :*****:***:. .*: * : *:** *****	59
EF_Tu-Frat	ITINTAHIEYETANRHYAHVDCPGHADYVKNMITGAAQMDGAILVCSAADGMPMQTREHI	120
EF_Tu-Rals.so	ITINTAHIEYETANRHYAHVDCPGHADYVKNMITGAAQMDGAILVCSAADGMPMQTREHI	120
EF_Tu-EColi	ITINTSHVEYDTPTRHYAHVDCPGHADYVKNMITGAAQMDGAILVVAATDGMPMQTREHI *****:*. *. ***** :*:*****	119
EF_Tu-Frat	LLARQVGVPYIIIVFLNKCDMVDDAELELVEMEVRELLSKYDFPGDDTPIIKGSAKLALE	180
EF_Tu-Rals.so	LLARQVGVPYIIIVFLNKCDMVDDAELELVEMEVRELLSKYDFPGDDTPIIKGSAKLALE	180
EF_Tu-EColi	LLGRQVGVPYIIIVFLNKCDMVDEELLELVEMEVRELLSQYDFPGDDTPIVRGSALKALE **.****** *****:*****:*** **	179
EF_Tu-Frat	GDKGELGETAIMSLADALDTYIPTPERAVDGTFLMPVEDVFISISGRGTVVTRGVVERGIIVK	240
EF_Tu-Rals.so	GDKGELGEVAIMNLADALDSYIPTPERAVDGTFLMPVEDVFISISGRGTVVTRIIRGGIIVK	240
EF_Tu-EColi	GD--AEWEAKILELAGFLDSYIPEPERAIDKPFLLPIEDVFISISGRGTVVTRGVVERGIIVK ** * . *:**. **:*** *****:*. *:*:*****:*****:*	237
EF_Tu-Frat	VGEEIEIVGIKDTQKTCTGVEMFRKLLDQGQAGDNVIGILLRGTKREDVERGQVLAKPGS	300
EF_Tu-Rals.so	VGEEIEIVGIKATQKTCTGVEMFRKLLDQGQAGDNVIGILLRGTKREDVERGQVLCKPGS	300
EF_Tu-EColi	VGEEVEIVGIKETQKSTCTGVEMFRKLLEDGRAGENVGVLRLGIKREEIERGQVLAKPGT ***:***** **:*****:*.**:***:*** **:*:*****.***:	297
EF_Tu-Frat	IKPHTHFTAENVVLSKDEGGRHTPFFNNYRPQFYFRTTDVTGSIELPKDKEMVMPPGDNVS	360
EF_Tu-Rals.so	IKPHTHFTGEVYILSKDEGGRHTPFFNNYRPQFYFRTTDVTGSIELPKDKEMVMPPGDNVS	360
EF_Tu-EColi	IKPHTKFESSEVYILSKDEGGRHTPFFKGYPQFYFRTTDVTGTIELPEGVEMVMPPGDNIK *****:* .***:*****:..*****:*****:..*****:.	357
EF_Tu-Frat	ITVKLIAPIAMEEGLRFAIREGGRTVGAGVVAKILD	396
EF_Tu-Rals.so	ITVKLIAPIAMEEGLRFAIREGGRTVGAGVVAKIIE	396
EF_Tu-EColi	MVVTLIHPIAMDDGLRFAIREGGRTVGAGVVAKVLG :.*.** *****:*****:*****:..*****:..*****:.	393

	Dissociation rate constant (k_{-I}) 10^{-4} s^{-1}	Dissociation half-lives (min)	Association rate constant (k_{+I}) $10^5 \text{ M}^{-1} \text{ s}^{-1}$	Dissociation constant (K_D) (nM)
EF-Tu•GDP (<i>E.coli</i>)	4.9 ± 0.04	22	2.5 ± 0.02	2
EF-Tu•GDP (<i>Frateuria</i> W-315)	2.0 ± 0.03	57	3.0 ± 0.03	0.7
EF-Tu•GDP (<i>E.coli</i>) + enacyloxin	7.2 ± 0.2	16	4.0 ± 0.12	1.8
EF-Tu•GDP <i>Frateuria</i> W-315) + enacyloxin	19.6 ± 1.2	6	4.3 ± 0.16	4.5
EF-Tu•GDP (<i>E.coli</i>) + kirromycin	7.7 ± 0.3	14	5.5 ± 0.3	1.4
EF-Tu•GDP (<i>Frateuria</i> W-315) + kirromycin	16.6 ± 0.9	6.7	4.7 ± 0.15	3.6
EF-Tu•GDP (<i>E.coli</i>) + pulvomycin	14 ± 0.4	6.5	6.1 ± 0.2	2.3
EF-Tu•GDP (<i>Frateuria</i> W-315) + pulvomycin	32.6 ± 2.1	3.5	11 ± 0.9	3
EF-Tu•GDP (<i>E.coli</i>) + GE2270A	5.2 ± 0.12	21	1.8 ± 0.05	2.9
EF-Tu•GDP (<i>Frateuria</i> W-315) + GE2270A	1.9 ± 0.03	58	0.8 ± 0.02	2.4

Table 2
Comparison of the Apparent Dissociation and Association Rate Constants and derived Equilibrium Constant ($K'_D = k'_{-1}/k'_{+1}$) of GTP complex of EF-Tu *E. coli* and EF-Tu *Frateruia* in the absence or presence of antibiotics.

	Dissociation rate constant (k'_{-1}) 10^{-4} s^{-1}	Dissociation half-lives (min)	Association rate constant (k'_{+1}) $10^4 \text{ M}^{-1} \text{ s}^{-1}$	Dissociation constant (K'_D) (nM)
EF-Tu•GTP (<i>E. coli</i>)	18 ± 0.9	6.3	0.76 ± 0.01	237
EF-Tu•GTP (<i>Frateruia</i> W-315)	21 ± 1.7	5.3	2.2 ± 0.03	95
EF-Tu•GTP (<i>E. coli</i>) + enacyloxin	5.5 ± 0.09	20.5	2.3 ± 1.6	2.5
EF-Tu•GTP (<i>Frateruia</i> W-315) + enacyloxin	6.3 ± 0.18	17.5	7.8 ± 0.2	8
EF-Tu•GTP (<i>E. coli</i>) + kirromycin	1.3 ± 0.02	89	15.2 ± 0.9	0.86
EF-Tu•GTP (<i>Frateruia</i> W-315) + kirromycin	1.0 ± 0.02	109	21 ± 1.4	0.48
EF-Tu•GTP (<i>E. coli</i>) + pulvomycin	1.7 ± 0.03	68.5	47 ± 2.6	0.36
EF-Tu•GTP (<i>Frateruia</i> W-315) + pulvomycin	1.7 ± 0.04	67	75.5 ± 5.4	0.22
EF-Tu•GTP (<i>E. coli</i>) + GE2270A	1.0 ± 0.01	107	5.2 ± 0.4	1.9
EF-Tu•GTP (<i>Frateruia</i> W-315) + GE2270A	0.93 ± 0.02	124	4.9 ± 0.3	2

determined by double reciprocal plots the concentration inducing half maximum activation (K_a) and the corresponding $V_{\max}$.

The concentration inducing half maximal activation were calculated to be 12 nM for EF-Tu *E. coli* and 71 nM for EF-Tu *Frateruia*. The maximal efficiency ($V_{\max}$) was the same for both EF-Tu species. (Fig. 5 and Table 3).

We analyzed the effect of various amino acid changes in EF-Tu *E. coli*, by replacing one or several amino acid residues in the 42–46 fragment by those of EF-Tu *Frateruia*.

As shown in Table 3 and Fig. 5, none of these substitutions affect the maximal level of activation. The single substitutions F46Y or Q48E do not modify the K_a value while the individual mutations A42E and A45K reduced slightly the affinity for the programmed ribosome. The effect of the double substitutions A42E/A45K and F46Y/Q48E is more pronounced in increasing the K_a value.

Introduction of the four mutations A42E/A45K/F46Y/Q48E increased the K_a to a value comparable with that of EF-Tu *Frateruia*.

3.5. Intrinsic GTPase activity: effect of Kirromycin, Enacyloxin, aminoacyl-tRNA and ribosome

GTPase activity was determined with preformed EF-Tu[γ - ^{32}P]•GTP.

Fig. 5. Comparison of Poly(U)-directed poly(phe) activation dependent of increasing concentrations of EF-Tu•GTP *E. coli* (●) EF-Tu•GTP *Frateruia* W315 (■) and EF-Tu•GTP *E. coli* A42E/A45K/F46Y/Q48E (▲). The final reaction mixture (30 μl) described in the Methods contained the indicated concentrations of the different species of EF-Tu in their GTP complex form, 0.25 μM EF-G, 0.2 μM EF-Ts, 0.3 μM 70S ribosome. EF-Tu•GTP complexes were preformed by incubating 2 μM EF-Tu•GDP at 30 °C for 10 min with 0.5 mM GTP, 1 mM 1 mM Phosphoenolpyruvate, 50 $\mu\text{g ml}^{-1}$ pyruvate Kinase in 40 mM Tris-HCl pH7.5, 7 mM MgCl_2 , 80 mM NH_4Cl , 1 mM dithiothreitol. The reaction was started by the addition of [^{14}C]PhetRNA^{Phe} and stopped after 10 min incubation at 30 °C under conditions of linear phe incorporation.

GTP complex and a large excess of [γ - ^{32}P]•GTP.

GTPase activities of EF-Tu *E. coli* and EF-Tu *Frateruia* were compared in the presence or in the absence of physiological partners like aa-tRNA or ribosomes, as well as in the presence of the antibiotics Kirromycin and Enacyloxin.

As shown in Table 4 and Fig. 6, intrinsic GTPase activity of EF-Tu *Frateruia* is almost 7 times higher than that of EF-Tu *E. coli*.

In our conditions, kirromycin enhances 10 times the k_{cat} value of the intrinsic GTPase activity of EF-Tu *E. coli*, while it enhances only 5 times the one of EF-Tu *Frateruia*. In contrast the antibiotic enacyloxin modestly enhances the GTPase activity of EF-Tu *E. coli* by a factor 2 and that of EF-Tu *Frateruia* by a factor of 3.5.

In the presence of phenylalanyl-tRNA^{Phe}, the intrinsic GTPase activities of EF-Tu *E. coli* and EF-Tu *Frateruia* were reduced by 50% and 30%, respectively, in agreement with previously reported data [27,28].

In the presence of kirromycin, the ribosomes stimulate the GTPase activity of the two EF-Tu species by a factor 8 (Table 4). However, in the presence of enacyloxin, the GTPase activities of EF-Tu *E. coli* and EF-Tu *Frateruia* were stimulated by the ribosomes by factors 40 and 13, respectively.

Among the naturally occurring amino acid changes between EF-Tu *E. coli* and EF-Tu *Frateruia* in the “effector region”, we have focused on the following: Ala-42, Ala-45, Phe-46 and Gln-48 in EF-Tu *E. coli* correspond respectively to Glu-42, Lys-45, Tyr-46 and Glu-48 in EF-Tu *Frateruia*. At each of these four positions, we have replaced the amino acid residue present in the *E. coli* factor by the one present in the *Frateruia* factor, and we have analyzed the effects of the mutations on the intrinsic GTPase activity of these mutant *E. coli* EF-Tu species.

The single A45K substitution did not modify the intrinsic GTPase activity of EF-Tu *E. coli*. In contrast, a 2–3 fold stimulation was

Table 3
Determination of the concentration of EF-Tu inducing half maximum activation (K_a) in Poly(U)-directed poly(phe) synthesis and corresponding $V_{\max}$. Comparison between EF-Tu *E. coli*, EF-Tu *Frateruia*, and the various mutants of EF-Tu *E. coli* in the « effector region ». The assays were performed as described in legend to Fig. 5. Values were calculated from double-reciprocal plots.

EF-Tu•GTP species	K_a (nM)	$V_{\max}$ (pmol $^{-1}$ min $^{-1}$)
EF-Tu <i>E. coli</i>	12 ± 0.8	8 ± 0.6
EF-Tu <i>Frateruia</i> W-315	71 ± 4.2	8.4 ± 0.5
EF-Tu E42	48 ± 3.2	8.3 ± 0.5
EF-Tu K45	37 ± 2.6	8.2 ± 0.6
EF-Tu E42/K45	54 ± 4.8	8.4 ± 0.7
EF-Tu Y46	13.5 ± 1.6	8.0 ± 0.9
EF-Tu E48	18 ± 2.1	8.2 ± 0.9
EF-Tu Y46/E48	63 ± 4.8	8.2 ± 0.6
EF-Tu E42/K45/Y46/E48	67 ± 5.1	8.6 ± 0.7

Table 4

Comparison of the K_{cat} of EF-Tu•GTP *E. coli*, EF-Tu•GTP *Frateruia* and EF-Tu•GTP *E. coli* mutants. In the *E. coli* mutants used, the amino acid residues naturally present in EF-Tu *E. coli* at given positions are replaced by the amino acid residues found at the same positions in EF-Tu *Frateruia*. GTPase activity was carried out as described in the Methods and in the legend to Fig. 6 in the absence or presence of 50 μ M kirromycin, 50 μ M enacyloxin IIa, 1 μ M Phe-tRNA^{Phe} and 1.5 μ M 70S ribosomes. Error of measurements lies between 8 and 15%.

	Intrinsic $k_{cat} \times 10^2(\text{min}^{-1})$	plus kirromycin $k_{cat} \times 10^2(\text{min}^{-1})$	plus enacyloxin $k_{cat} \times 10^2(\text{min}^{-1})$	plus PhetRNAPhe $k_{cat} \times 10^2(\text{min}^{-1})$	plus ribosome plus kirromycin $k_{cat} \times 10^2(\text{min}^{-1})$	plus ribosome plus enacyloxin $k_{cat} \times 10^2(\text{min}^{-1})$
EF-Tu <i>E. coli</i>	1.4	13.5	2.5	0.71	118	103
EF-Tu <i>Frateruia</i> W-315	9.4	44.5	32	6.6	346	420
EF-Tu <i>E. coli</i> A42E	3.0	50	21.2			
EF-Tu <i>E. coli</i> A45K	1.6	20	4			
EF-Tu <i>E. coli</i> A42E/A45K	1.6	27	8			
EF-Tu <i>E. coli</i> F46Y	4.3	63	11			
EF-Tu <i>E. coli</i> Q48E	3.0	40	13.6			
EF-Tu <i>E. coli</i> F46Y/Q48E	4.9	96	26.4			
EF-Tu <i>E. coli</i> A42E/ A45K/F46Y/Q48E	9.5	160	62			

observed with the single A42E, F46Y, Q48E and the double F46Y/Q48E substitutions. Finally, up to a 7 fold stimulation was observed with the quadruple substitution (mutant A42E/A45K/F46Y/Q48E).

Stimulation of the intrinsic GTPase activity of EF-Tu *E. coli* in the presence of kirromycin was increased 3.7, 3 and 5 fold respectively, by the single A42E, Q48E and F46Y substitutions, while the stimulation was increased 7 and 12 fold respectively, by the double (F46Y/Q48E) and the quadruple (A42E/A45K/F46Y/Q48E) substitutions.

While enacyloxin increased modestly the GTPase activity of the wild type *E. coli* EF-Tu (less than 2 fold), introduction of single or multiple substitutions enhanced the catalytic activity, especially with the double (F46Y/Q48E) and the quadruple (A42E/A45K/F46Y/Q48E) substitutions where a 10 fold and a 25 fold stimulations were observed, respectively. These results suggest that amino acid substitutions in the “effector region” affect the catalytic GTPase activity of the *E. coli* factor.

4. Discussion

Frateruia sp. W-315 is a Gammaproteobacterium of the family Xanthomonadaceae. It is an intermediate strain among the genera *Gluconobacter*, *Pseudomonas* and *Acetobacter* [29]. It produces a family of polyenic antibiotics named enacyloxin active against Gram positive and Gram-negative microorganisms [6]. Among them enacyloxin IIa has been shown to inhibit bacterial protein biosynthesis *in vitro* [8]. Enacyloxin has a mechanism of action similar to that of the antibiotic kirromycin because it inhibits protein synthesis by acting on a specific target, the translation factor EF-Tu. Enacyloxin induces a constitutive activation of EF-Tu•GDP, making this complex so firmly attached to the mRNA-programmed ribosomes after aa-tRNA binding and GTP hydrolysis, that recycling of EF-Tu•GDP and peptide bond formation are inhibited [9]. It is generally accepted that an organism that produces an antibiotic would not be sensitive to this molecule. Therefore, it is not surprising that the enacyloxin producing *Frateruia* W-315 strain is resistant to this antibiotic. However, the molecular mechanism of this resistance is not yet elucidated. In this context, taking into account the general increase in resistance toward antibiotics, and considering that the resistance of the enacyloxin producing *Frateruia* W-315 strain might stem from structural elements specific to EF-Tu, we have purified the factor from *Frateruia* W-315 and shown that it was as sensitive to enacyloxin as *E. coli* EF-Tu in *in vitro* poly(Phe) synthesis with a IC_{50} of 0.2 μ M. The same results were obtained in the presence of enacyloxin IIa or in the presence of its intermediate biosynthesized form enacyloxin IVa, with S30 extracts of *Frateruia* W-315 suggesting that resistance to the antibiotic of

enacyloxin producing *Frateruia* W-315 is not linked to its target EF-Tu or to other component of the translational machinery. Therefore, it is most probable that the resistance to enacyloxin is due to an active secretion factor that removes quickly the antibiotic from the cytosol.

We can mention that none of the residues (K124, D316, T375) identified on *E. coli* EF-Tu responsible for enacyloxin resistance [16] are present in the amino acid sequence of *Frateruia* EF-Tu.

EF-Tu *E. coli* folds in three domains: the nucleotide-binding domain 1 (residues 1–199) contains an α/β Rossman fold with four α -helices A, B, C and D, as well as the “effector region” (residues 41–65), whereas domains 2 and 3 (residues 209–299 and 300–393, respectively) are β -barrels. The binding site of Enacyloxin IIa located at the interface of domains 1 and 3 overlaps that of kirromycin [30]. On the basis of strong primary structure similarities between EF-Tu *Frateruia* and EF-Tu *Ralstonia solanacearum*, as revealed by mass spectrometric analyses, we have cloned and sequenced the gene coding for EF-Tu *Frateruia*. The amino acid sequence of the latter shows 80% identity with EF-Tu *E. coli* and 97% with EF-Tu *Ralstonia*. Only few differences occurred in fragment 36–48 belonging to the “effector region” and in fragment 182–186 located in domain 1 of the factor.

In spite of these strong primary structure similarities, EF-Tu *E. coli* was shown to be more efficient than EF-Tu *Frateruia* in stimulating protein synthesis *in vitro*, suggesting that some key amino acid residues involved in catalysis might be different in the two factors. For example, when the Phe residue at position 46 or the Gln residue at position 48 in EF-Tu *E. coli* were changed to Tyr or Glu (the amino acid residues naturally present at these positions in EF-Tu *Frateruia*), respectively, the concentration inducing half maximal activation in poly(Phe) synthesis was not affected, suggesting that these substitutions operated in the “effector region” are not critical for the function of the factor. By contrast, changing Ala to Glu at position 42 and Ala to Lys at position 45 were shown to decrease the efficiency of EF-Tu *E. coli*. Taking into account the fact that Glu and Lys are charged residues and that their side chains are much larger than that of Ala, these results would be the reflect of structural requirements in the “effector region” of EF-Tu. The aforementioned effects were even more pronounced with the quadruple (A42E/A45K/F46Y/Q48E) substitutions, with a k_a value of EF-Tu *E. coli* becoming almost equal to that of EF-Tu *Frateruia*. Altogether, these results suggest that the residues Glu-42, Lys-45, Tyr-46 and Glu-48 participate to the binding pocket for the effector in the 3-D structure of EF-Tu *Frateruia*.

EF-Tu is the target of four families of antibiotics of unrelated structures inhibiting protein synthesis. Their prototypes are kirromycin, enacyloxin IIa, pulvomycin and GE2270A [10]. All these

Fig. 6. Intrinsic GTPase activity of EF-Tu *E. coli* (□), EF-Tu *Frateuria* W315 (Δ) and EF-Tu *Coli A43E/A46K/F47Y/Q49E* (○) in the absence (A) or in the presence of 50 μM kirromycin (B) or 50 μM enacyloxin IIa (C). The hydrolysis of [γ - 32 P]•GTP was determined as described in the methods. The concentration of preformed EF-Tu•[γ - 32 P]•GTP complex was determined by nitrocellulose binding assay from the radioactivity bound to EF-Tu products in the presence of a saturating amount of [γ - 32 P]•GTP (500 μM–20 Bq pmol $^{-1}$) in 40 mM Tris-HCl pH 7.5, 7 mM MgCl $_2$, 80 mM NH $_4$ Cl, 2 mM Phosphoenolpyruvate, 100 μg ml $^{-1}$ pyruvate Kinase, 1 mM dithiothreitol, 0.05 mg ml $^{-1}$ BSA after 10 min at 30 °C.

antibiotics strongly increase the affinity of EF-Tu•GTP by affecting the apparent association and dissociation rates in opposite ways, the association rate being strongly stimulated, while the dissociation rate is inhibited. The effect of these different antibiotics on the stimulation of the apparent GTP association rate is lower with EF-Tu *Frateuria* than with EF-Tu *E. coli*, while the effect on the dissociation rate is of the same order of magnitude. In the case of the antibiotic enacyloxin, the effect on the stimulation of the association rate was

8 times less important with EF-Tu *Frateuria* than with EF-Tu *E. coli*. With the exception of the antibiotic GE2270A, all the antibiotics exert a stronger effect on the stimulation of the apparent GDP dissociation rate of EF-Tu *Frateuria* in comparison with EF-Tu *E. coli*. These results would suggest that, inspite of the high degree of structural conservation, it exists some variations in the binding mode of the antibiotics on EF-Tu *Frateuria* and EF-Tu *E. coli*.

Conserved Thr-25 is involved in the coordination of the essential magnesium ion interacting with the β - and γ -phosphates of the GTP nucleotide in the hydrophobic guanine binding pocket of the factor [31–34]. It is most probable that the modification of the effector loop structure in EF-Tu *Frateuria* results in a loss of hydrophobic contacts with the Thr-25 side chain methyl group that might affect the kinetics of interaction with the guanine nucleotides. Antibiotics bind at the interface between domains 1 and 3 of EF-Tu and destabilize the effector region by changing its conformation [30,35]. They contact the domain 1 interface representing a strategic region which communicates with the nucleotide binding pocket via the switch regions, and mediates the GDP and GTP dependent signals controlling the interactions with ligands.

In the present report, enacyloxin IIa was shown to enhance the intrinsic GTPase activity of EF-Tu *E. coli*, much more weakly than kirromycin. GTP hydrolysis in EF-Tu takes place through an in line direct attack on the γ -phosphate by a water molecule. His-84 has been proposed to be involved in EF-Tu-mediated GTPase activity through a nucleophilic attack of its side chain on the γ -phosphate [11, 31, 36]. However analysis of the GTPase activity of the EF-Tu•antibiotic complexes and of H84 mutants in the absence or in the presence of programmed ribosomes did not support a direct involvement of the H84 side chain in the GTP γ -phosphate hydrolysis [10,37,38]. All the antibiotics (kirromycin, enacyloxin, pulvomycin) that enhance the intrinsic GTPase activity of EF-Tu interact with the domain 1:3 interface. Perturbation of this area in close contact with the nucleotide binding pocket via the switch regions could influence the cleavage of the GTP γ -phosphate. GTPase activation is controlled by a hydrophobic gate formed by residues Val-20 in the P-loop region and Ile-60 in the switch I effector region which prevents His-84 from activating the water molecule and the catalysis of GTP hydrolysis.

Switch 1 region (residues 40–62) displays conformational changes in the working cycle of EF-Tu. The prominent structural differences between EF-Tu *E. coli* and EF-Tu *Frateuria* are located in the switch 1 region. This structural modification in switch 1 in EF-Tu *Frateuria* can affect the flexibility of this region and facilitate the opening gate and the access of His-84 to the nucleotide. As a consequence, the GTPase activity of EF-Tu *Frateuria* might be increased in comparison with that of EF-Tu *E. coli*. In line with this, mutations in this region that replaced residues in EF-Tu *E. coli* by those of EF-Tu *Frateuria* activate intrinsic GTP hydrolysis and antibiotics dependent stimulation. Crystallographic studies of EF-Tu *Frateuria* in complex with the non hydrolysable GTP and/or with antibiotics will bring further insight into the GTPase mechanism.

Acknowledgments

We are indebted to Dr T. Watanabe and colleagues for the gift of the strain *Frateuria* sp.W-315. We gratefully thank A. Parmeggiani and S. Baouz for suggestions and for critical reading of the manuscript.

References

- [1] D.N. Wilson, K.H. Nierhaus, The ribosome through the looking glass, *Angew. Chem. Int. Ed. Engl.* 42 (2003) 3464–3486.
- [2] J. Nilsson, P. Nissen, Elongation factors on the ribosome, *Curr. Opin. Struct.*

- Biol. 15 (2005) 349–354.
- [3] D. Kavaliuskas, P. Nissen, C.R. Knudsen, The busiest of all ribosomal assistants: elongation factor Tu, *Biochemistry* 51 (2012) 2642–2651.
 - [4] A. Bashan, I. Agmon, R. Zarivach, F. Schlutzen, J. Harms, R. Berisio, H. Bartels, F. Franceschi, T. Auerbach, H.A. Hansen, E. Kossoy, M. Kessler, A. Yonath, Structural basis of the ribosomal machinery for peptide bond formation, translocation, and nascent chain progression, *Mol. Cell* 11 (2003) 91–102.
 - [5] A. Parmeggiani, P. Nissen, Elongation factor Tu-targeted antibiotics: four different structures, two mechanisms of action, *FEBS Lett.* 580 (2006) 4576–4581.
 - [6] T. Watanabe, K. Izaki, H. Takahashi, New polyenic antibiotics active against gram-positive and -negative bacteria. I. Isolation and purification of antibiotics produced by *Gluconobacter* sp. W-315, *J. Antibiot. (Tokyo)* 35 (1982) 1141–1147.
 - [7] T. Watanabe, N. Okubo, T. Suzuki, K. Izaki, New polyenic antibiotics active against gram-positive and gram-negative bacteria. VI. Non-lactonic polyene antibiotic, enacyloxin IIa, inhibits binding of aminoacyl-tRNA to A site of ribosomes, *J. Antibiot. (Tokyo)* 45 (1992) 572–574.
 - [8] T. Watanabe, T. Suzuki, K. Izaki, New polyenic antibiotics active against gram-positive and gram-negative bacteria. V. Mode of action of enacyloxin IIa, *J. Antibiot. (Tokyo)* 44 (1991) 1457–1459.
 - [9] R. Cetin, I.M. Krab, P.H. Anborgh, R.H. Cool, T. Watanabe, T. Sugiyama, K. Izaki, A. Parmeggiani, Enacyloxin IIa, an inhibitor of protein biosynthesis that acts on elongation factor Tu and the ribosome, *EMBO J.* 15 (1996) 2604–2611.
 - [10] I.M. Krab, A. Parmeggiani, Mechanisms of EF-Tu, a pioneer GTPase, *Prog. Nucleic Acid. Res. Mol. Biol.* 71 (2002) 513–551.
 - [11] T. Hogg, J.R. Mesters, R. Hilgenfeld, Inhibitory mechanisms of antibiotics targeting elongation factor Tu, *Curr. Protein Pept. Sci.* 3 (2002) 121–131.
 - [12] H. Wolf, D. Assmann, E. Fischer, Pulvomycin, an inhibitor of protein biosynthesis preventing ternary complex formation between elongation factor Tu, GTP, and aminoacyl-tRNA, *Proc. Natl. Acad. Sci. U. S. A.* 75 (1978) 5324–5328.
 - [13] P.H. Anborgh, A. Parmeggiani, New antibiotic that acts specifically on the GTP-bound form of elongation factor Tu, *EMBO J.* 10 (1991) 779–784.
 - [14] P.H. Anborgh, S. Okamura, A. Parmeggiani, Effects of the antibiotic pulvomycin on the elongation factor Tu-dependent reactions. Comparison with other antibiotics, *Biochemistry* 43 (2004) 15550–15556.
 - [15] A. Parmeggiani, I.M. Krab, S. Okamura, R.C. Nielsen, J. Nyborg, P. Nissen, Structural basis of the action of pulvomycin and GE2270 A on elongation factor Tu, *Biochemistry* 45 (2006) 6846–6857.
 - [16] A.M. Zuurmond, L.N. Olsthoorn-Tieleman, J. Martien de Graaf, A. Parmeggiani, B. Kraal, Mutant EF-Tu species reveal novel features of the enacyloxin IIa inhibition mechanism on the ribosome, *J. Mol. Biol.* 294 (1999) 627–637.
 - [17] M. Salanoubat, S. Genin, F. Artiguenave, J. Gouzy, S. Mangenot, M. Arlat, A. Billault, P. Brottier, J.C. Camus, L. Cattolico, M. Chandler, N. Choisine, C. Claudel-Renard, S. Cunnac, N. Demange, C. Gaspin, M. Lavie, A. Moisan, C. Robert, W. Saurin, T. Schiex, P. Sigui, P. Thebault, M. Whalen, P. Wincker, M. Levy, J. Weissenbach, C.A. Boucher, Genome sequence of the plant pathogen *Ralstonia solanacearum*, *Nature* 415 (2002) 497–502.
 - [18] I.M. Krab, A. Parmeggiani, Functional-structural analysis of threonine 25, a residue coordinating the nucleotide-bound magnesium in elongation factor Tu, *J. Biol. Chem.* 274 (1999) 11132–11138.
 - [19] P.H. Anborgh, A. Parmeggiani, Probing the reactivity of the GTP- and GDP-bound conformations of elongation factor Tu in complex with the antibiotic GE2270 A, *J. Biol. Chem.* 268 (1993) 24622–24628.
 - [20] R.J. Smith, D.H. Williams, J.C.J. Barna, I.R. McDermott, K.D. Haeghele, F. Piriou, J. Wagner, W. Higgins, Structure revision of the antibiotic Pulvomycin, *J. Am. Chem. Soc.* 107 (1985) 2849–2857.
 - [21] G. Chinali, A. Parmeggiani, Properties of the elongation factors from *Escherichia coli*. Exchange of elongation factor G during elongation of polypeptide chain, *Eur. J. Biochem.* 32 (1973) 463–472.
 - [22] I.M. Krab, R. te Biesebeke, A. Bernardi, A. Parmeggiani, Elongation factor Ts can act as a steric chaperone by increasing the solubility of nucleotide binding-impaired elongation factor-Tu, *Biochemistry* 40 (2001) 8531–8535.
 - [23] J.B. Crechet, D. Canceill, V. Bocchini, A. Parmeggiani, Characterization of the elongation factors from calf brain. 1. Purification, molecular and immunological properties, *Eur. J. Biochem.* 161 (1986) 635–645.
 - [24] O. Fasano, W. Bruns, J.B. Crechet, G. Sander, A. Parmeggiani, Modification of elongation-factor-Tu. guanine-nucleotide interaction by kirromycin. A comparison with the effect of aminoacyl-tRNA and elongation factor Ts, *Eur. J. Biochem.* 89 (1978) 557–565.
 - [25] R. Oyama, T. Watanabe, H. Hanzawa, T. Sano, T. Sugiyama, K. Izaki, An extracellular Quinoprotein oxidase that catalyses conversion of Enacyloxin IVa to Enacyloxin IIa, *Biosci. Biotechnol. Biochem.* 58 (1994) 1914–1917.
 - [26] H. Wolf, G. Chinali, A. Parmeggiani, Mechanism of the inhibition of protein synthesis by kirromycin. Role of elongation factor Tu and ribosomes, *Eur. J. Biochem.* 75 (1977) 67–75.
 - [27] D. Picone, A. Parmeggiani, Transfer ribonucleic acid deprived of the C-C-A 3'-extremity can interact with elongation factor Tu, *Biochemistry* 22 (1983) 4400–4405.
 - [28] O. Fasano, J.B. Crechet, A. Parmeggiani, Preparation of nucleotide-free elongation factor Tu and its stabilization by the antibiotic kirromycin, *Anal. Biochem.* 124 (1982) 53–58.
 - [29] T. Watanabe, T. Sugiyama, K. Izaki, New polyenic antibiotics active against gram-positive and gram-negative bacteria. IX. Reclassification of a strain W-315 producing enacyloxins, *J. Antibiot. (Tokyo)* 47 (1994) 496–498.
 - [30] A. Parmeggiani, I.M. Krab, T. Watanabe, R.C. Nielsen, C. Dahlberg, J. Nyborg, P. Nissen, Enacyloxin IIa pinpoints a binding pocket of elongation factor Tu for development of novel antibiotics, *J. Biol. Chem.* 281 (2006) 2893–2900.
 - [31] H. Berchtold, L. Reshetnikova, C.O. Reiser, N.K. Schirmer, M. Sprinzl, R. Hilgenfeld, Crystal structure of active elongation factor Tu reveals major domain rearrangements, *Nature* 365 (1993) 126–132.
 - [32] M. Kjeldgaard, P. Nissen, S. Thirup, J. Nyborg, The crystal structure of elongation factor EF-Tu from *Thermus aquaticus* in the GTP conformation, *Structure* 1 (1993) 35–50.
 - [33] K. Abel, M.D. Yoder, R. Hilgenfeld, F. Jurnak, An alpha to beta conformational switch in EF-Tu, *Structure* 4 (1996) 1153–1159.
 - [34] G. Polekhina, S. Thirup, M. Kjeldgaard, P. Nissen, C. Lippmann, J. Nyborg, Helix unwinding in the effector region of elongation factor EF-Tu-GDP, *Structure* 4 (1996) 1141–1151.
 - [35] L. Vogeley, G.J. Palm, J.R. Mesters, R. Hilgenfeld, Conformational change of elongation factor Tu (EF-Tu) induced by antibiotic binding. Crystal structure of the complex between EF-Tu.GDP and aurodox, *J. Biol. Chem.* 276 (2001) 17149–17155.
 - [36] T. Daviter, H.J. Wieden, M.V. Rodnina, Essential role of histidine 84 in elongation factor Tu for the chemical step of GTP hydrolysis on the ribosome, *J. Mol. Biol.* 332 (2003) 689–699.
 - [37] R.H. Cool, A. Parmeggiani, Substitution of histidine-84 and the GTPase mechanism of elongation factor Tu, *Biochemistry* 30 (1991) 362–366.
 - [38] G. Scarano, I.M. Krab, V. Bocchini, A. Parmeggiani, Relevance of histidine-84 in the elongation factor Tu GTPase activity and in poly(Phe) synthesis: its substitution by glutamine and alanine, *FEBS Lett.* 365 (1995) 214–218.